Reported Earnings • May 20
First quarter 2026 earnings released: JP¥14.34 loss per share (vs JP¥18.56 loss in 1Q 2025) First quarter 2026 results: JP¥14.34 loss per share (improved from JP¥18.56 loss in 1Q 2025). Revenue: JP¥907.0m (down 8.9% from 1Q 2025). Net loss: JP¥79.0m (loss narrowed 26% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 97 percentage points per year, which is a significant difference in performance. Reported Earnings • Mar 28
Full year 2025 earnings released: EPS: JP¥9.77 (vs JP¥56.52 loss in FY 2024) Full year 2025 results: EPS: JP¥9.77 (up from JP¥56.52 loss in FY 2024). Revenue: JP¥4.19b (flat on FY 2024). Net income: JP¥55.0m (up JP¥364.0m from FY 2024). Profit margin: 1.3% (up from net loss in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 98 percentage points per year, which is a significant difference in performance. Reported Earnings • Feb 16
Full year 2025 earnings released: EPS: JP¥9.77 (vs JP¥56.52 loss in FY 2024) Full year 2025 results: EPS: JP¥9.77 (up from JP¥56.52 loss in FY 2024). Revenue: JP¥4.19b (flat on FY 2024). Net income: JP¥55.0m (up JP¥364.0m from FY 2024). Profit margin: 1.3% (up from net loss in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 100 percentage points per year, which is a significant difference in performance. Announcement • Feb 13
MRT Inc., Annual General Meeting, Mar 24, 2026 MRT Inc., Annual General Meeting, Mar 24, 2026. Announcement • Jan 07
MRT Inc. to Report Fiscal Year 2025 Results on Feb 13, 2026 MRT Inc. announced that they will report fiscal year 2025 results on Feb 13, 2026 Announcement • Nov 18
MRT Inc. (TSE:6034) announces an Equity Buyback for 130,000 shares, representing 2.27% for ¥110 million. MRT Inc. (TSE:6034) announces a share repurchase program. Under the program, the company will repurchase up to 130,000 shares, representing 2.27% of its issued share capital, for ¥110 million. The purpose of the program is to implement a flexible capital policy that responds to changes in the business environment, to improve capital efficiency, and to provide returns to shareholders. The plan will expire on May 14, 2026. As of September 30, 2025, there are 5,718,600 outstanding shares (excluding treasury stock) and treasury stock 131,120 shares. Reported Earnings • Nov 18
Third quarter 2025 earnings released: EPS: JP¥0.18 (vs JP¥17.63 loss in 3Q 2024) Third quarter 2025 results: EPS: JP¥0.18 (up from JP¥17.63 loss in 3Q 2024). Revenue: JP¥938.0m (flat on 3Q 2024). Net income: JP¥1.00m (up JP¥97.0m from 3Q 2024). Profit margin: 0.1% (up from net loss in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance. Announcement • Oct 08
MRT Inc. to Report Q3, 2025 Results on Nov 14, 2025 MRT Inc. announced that they will report Q3, 2025 results on Nov 14, 2025 Reported Earnings • Aug 16
Second quarter 2025 earnings released: EPS: JP¥32.10 (vs JP¥18.00 in 2Q 2024) Second quarter 2025 results: EPS: JP¥32.10 (up from JP¥18.00 in 2Q 2024). Revenue: JP¥1.33b (up 3.7% from 2Q 2024). Net income: JP¥181.0m (up 85% from 2Q 2024). Profit margin: 14% (up from 7.6% in 2Q 2024). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance. New Risk • Jul 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 22% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.0% average weekly change). Market cap is less than US$100m (JP¥3.99b market cap, or US$27.1m). Announcement • Jul 03
MRT Inc. to Report Q2, 2025 Results on Aug 14, 2025 MRT Inc. announced that they will report Q2, 2025 results on Aug 14, 2025 Reported Earnings • May 21
First quarter 2025 earnings released: JP¥18.56 loss per share (vs JP¥12.12 loss in 1Q 2024) First quarter 2025 results: JP¥18.56 loss per share (further deteriorated from JP¥12.12 loss in 1Q 2024). Revenue: JP¥996.0m (up 6.3% from 1Q 2024). Net loss: JP¥106.0m (loss widened 61% from 1Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance. Announcement • Apr 23
MRT Inc. to Report Q1, 2025 Results on May 15, 2025 MRT Inc. announced that they will report Q1, 2025 results on May 15, 2025 Announcement • Feb 17
MRT Inc., Annual General Meeting, Mar 25, 2025 MRT Inc., Annual General Meeting, Mar 25, 2025. Reported Earnings • Feb 17
Full year 2024 earnings released: JP¥56.52 loss per share (vs JP¥94.40 profit in FY 2023) Full year 2024 results: JP¥56.52 loss per share (down from JP¥94.40 profit in FY 2023). Revenue: JP¥4.17b (down 23% from FY 2023). Net loss: JP¥309.0m (down 160% from profit in FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance. Announcement • Jan 31
MRT Inc. (TSE:6034) announces an Equity Buyback for 130,000 shares, representing 2.27% for ¥120 million. MRT Inc. (TSE:6034) announces a share repurchase program. Under the program, the company will repurchase up to 130,000 shares, representing 2.27% of its issued share capital, for ¥120 million. The purpose of the program is to implement a flexible capital policy that responds to changes in the business environment, to improve capital efficiency, and to provide returns to shareholders. The plan will expire on August 29, 2025. As of December 31, 2024, there are 5,718,600 outstanding shares (excluding treasury stock) and treasury stock 1,070 shares. Announcement • Jan 21
MRT Inc. to Report Fiscal Year 2024 Results on Feb 14, 2025 MRT Inc. announced that they will report fiscal year 2024 results on Feb 14, 2025 New Risk • Jan 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.1% average weekly change). Market cap is less than US$100m (JP¥3.86b market cap, or US$24.8m). Announcement • Nov 16
MRT Inc. announced that it expects to receive ¥215.46 million in funding from ITOCHU Corporation MRT Inc. announced announced a private placement to issue 270,000 common shares at issue price of ¥798 per share for gross proceeds of ¥215,460,000 on November 14, 2024. The transaction includes participation from new investor, Itochu Corporation. The transaction will happen through third party allocation. The issue date will be December 3, 2024. The transaction has been approved at board of director meeting of the company. The company will bear issuance sundry expenses of ¥1,576,000 and will receive net proceeds of ¥213,884,000. Announcement • Nov 06
MRT Inc. to Report Q3, 2024 Results on Nov 14, 2024 MRT Inc. announced that they will report Q3, 2024 results on Nov 14, 2024 Reported Earnings • Aug 19
Second quarter 2024 earnings released: EPS: JP¥18.00 (vs JP¥41.45 in 2Q 2023) Second quarter 2024 results: EPS: JP¥18.00 (down from JP¥41.45 in 2Q 2023). Revenue: JP¥1.28b (down 13% from 2Q 2023). Net income: JP¥98.0m (down 57% from 2Q 2023). Profit margin: 7.6% (down from 15% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings. Announcement • Aug 07
MRT Inc. to Report Q2, 2024 Results on Aug 14, 2024 MRT Inc. announced that they will report Q2, 2024 results on Aug 14, 2024 Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to JP¥574, the stock trades at a trailing P/E ratio of 19.5x. Average trailing P/E is 15x in the Healthcare industry in Japan. Total loss to shareholders of 62% over the past three years. New Risk • Aug 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (26% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Profit margins are more than 30% lower than last year (3.5% net profit margin). Market cap is less than US$100m (JP¥3.82b market cap, or US$25.7m). Reported Earnings • May 19
First quarter 2024 earnings released: JP¥12.12 loss per share (vs JP¥52.29 profit in 1Q 2023) First quarter 2024 results: JP¥12.12 loss per share (down from JP¥52.29 profit in 1Q 2023). Revenue: JP¥937.0m (down 47% from 1Q 2023). Net loss: JP¥66.0m (down 123% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Announcement • May 15
MRT Inc. to Report Q1, 2024 Results on May 15, 2024 MRT Inc. announced that they will report Q1, 2024 results on May 15, 2024 Reported Earnings • Feb 17
Full year 2023 earnings released: EPS: JP¥94.40 (vs JP¥387 in FY 2022) Full year 2023 results: EPS: JP¥94.40 (down from JP¥387 in FY 2022). Revenue: JP¥5.41b (down 38% from FY 2022). Net income: JP¥517.0m (down 76% from FY 2022). Profit margin: 9.6% (down from 25% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Announcement • Feb 16
MRT Inc., Annual General Meeting, Mar 26, 2024 MRT Inc., Annual General Meeting, Mar 26, 2024. Announcement • Jan 21
MRT Inc. to Report Fiscal Year 2023 Results on Feb 15, 2024 MRT Inc. announced that they will report fiscal year 2023 results on Feb 15, 2024 Reported Earnings • Nov 19
Third quarter 2023 earnings released: EPS: JP¥15.62 (vs JP¥65.84 in 3Q 2022) Third quarter 2023 results: EPS: JP¥15.62 (down from JP¥65.84 in 3Q 2022). Revenue: JP¥1.11b (down 28% from 3Q 2022). Net income: JP¥85.0m (down 77% from 3Q 2022). Profit margin: 7.7% (down from 24% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Announcement • Nov 09
MRT Inc. to Report Q3, 2023 Results on Nov 14, 2023 MRT Inc. announced that they will report Q3, 2023 results on Nov 14, 2023 Reported Earnings • Aug 12
Second quarter 2023 earnings released: EPS: JP¥43.09 (vs JP¥143 in 2Q 2022) Second quarter 2023 results: EPS: JP¥43.09 (down from JP¥143 in 2Q 2022). Revenue: JP¥1.47b (down 53% from 2Q 2022). Net income: JP¥235.0m (down 70% from 2Q 2022). Profit margin: 16% (down from 26% in 2Q 2022). The decrease in margin was driven by lower revenue. Announcement • Aug 10
MRT Inc. to Report Q2, 2023 Results on Aug 10, 2023 MRT Inc. announced that they will report Q2, 2023 results on Aug 10, 2023 Reported Earnings • May 20
First quarter 2023 earnings released: EPS: JP¥52.29 (vs JP¥103 in 1Q 2022) First quarter 2023 results: EPS: JP¥52.29 (down from JP¥103 in 1Q 2022). Revenue: JP¥1.77b (down 24% from 1Q 2022). Net income: JP¥291.0m (down 49% from 1Q 2022). Profit margin: 17% (down from 25% in 1Q 2022). The decrease in margin was driven by lower revenue. Board Change • Apr 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. Independent Outside Director Pablo Sebastian Ortega was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Announcement • Feb 18
MRT Inc., Annual General Meeting, Mar 28, 2023 MRT Inc., Annual General Meeting, Mar 28, 2023. Reported Earnings • Feb 17
Full year 2022 earnings released: EPS: JP¥387 (vs JP¥139 in FY 2021) Full year 2022 results: EPS: JP¥387 (up from JP¥139 in FY 2021). Revenue: JP¥8.74b (up 96% from FY 2021). Net income: JP¥2.16b (up 179% from FY 2021). Profit margin: 25% (up from 17% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Reported Earnings • Nov 16
Third quarter 2022 earnings released: EPS: JP¥65.84 (vs JP¥90.61 in 3Q 2021) Third quarter 2022 results: EPS: JP¥65.84 (down from JP¥90.61 in 3Q 2021). Revenue: JP¥1.54b (down 4.3% from 3Q 2021). Net income: JP¥367.0m (down 27% from 3Q 2021). Profit margin: 24% (down from 31% in 3Q 2021). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth. Reported Earnings • Nov 13
Third quarter 2022 earnings released: EPS: JP¥66.02 (vs JP¥90.61 in 3Q 2021) Third quarter 2022 results: EPS: JP¥66.02 (down from JP¥90.61 in 3Q 2021). Revenue: JP¥1.54b (down 4.3% from 3Q 2021). Net income: JP¥368.0m (down 27% from 3Q 2021). Profit margin: 24% (down from 31% in 3Q 2021). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth. Announcement • Nov 09
MRT Inc. to Report Q3, 2022 Results on Nov 11, 2022 MRT Inc. announced that they will report Q3, 2022 results on Nov 11, 2022 Valuation Update With 7 Day Price Move • Aug 19
Investor sentiment improved over the past week After last week's 41% share price gain to JP¥2,073, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 14x in the Healthcare industry in Japan. Total returns to shareholders of 141% over the past three years. Reported Earnings • Aug 15
Second quarter 2022 earnings released: EPS: JP¥143 (vs JP¥44.84 in 2Q 2021) Second quarter 2022 results: EPS: JP¥143 (up from JP¥44.84 in 2Q 2021). Revenue: JP¥3.11b (up 180% from 2Q 2021). Net income: JP¥795.0m (up 219% from 2Q 2021). Profit margin: 26% (up from 22% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jul 21
Investor sentiment improved over the past week After last week's 22% share price gain to JP¥1,466, the stock trades at a trailing P/E ratio of 5.9x. Average trailing P/E is 13x in the Healthcare industry in Japan. Total returns to shareholders of 64% over the past three years. Announcement • Jul 06
MRT Inc. to Report Q2, 2022 Results on Aug 12, 2022 MRT Inc. announced that they will report Q2, 2022 results on Aug 12, 2022 Valuation Update With 7 Day Price Move • May 20
Investor sentiment improved over the past week After last week's 16% share price gain to JP¥1,106, the stock trades at a trailing P/E ratio of 4.4x. Average trailing P/E is 13x in the Healthcare industry in Japan. Total returns to shareholders of 19% over the past three years. Reported Earnings • May 16
First quarter 2022 earnings released: EPS: JP¥103 (vs JP¥7.56 loss in 1Q 2021) First quarter 2022 results: EPS: JP¥103 (up from JP¥7.56 loss in 1Q 2021). Revenue: JP¥2.33b (up 340% from 1Q 2021). Net income: JP¥574.0m (up JP¥616.0m from 1Q 2021). Profit margin: 25% (up from net loss in 1Q 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Board Change • Apr 27
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 3 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Outside Director Pablo Sebastian Ortega was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Apr 08
MRT Inc. to Report Q1, 2022 Results on May 13, 2022 MRT Inc. announced that they will report Q1, 2022 results on May 13, 2022 Announcement • Feb 25
MRT Inc. (TSE:6034) announces an Equity Buyback for 150,000 shares, representing 2.62% for ¥170 million. MRT Inc. (TSE:6034) announces a share repurchase program. Under the program, the company will repurchase up to 150,000 shares, representing 2.62% of its issued share capital, for ¥170 million. The purpose of the program is to implement agile capital policies in response to changes in the business environment, improve capital efficiency, and return profits to shareholders. The program will expire on April 11, 2022. As of December 31, 2021, the company had 5,714,800 issued shares (excluding treasury stock) and 141,030 treasury shares. Reported Earnings • Feb 20
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: JP¥135 (up from JP¥23.59 in FY 2020). Revenue: JP¥4.47b (up 74% from FY 2020). Net income: JP¥753.0m (up 475% from FY 2020). Profit margin: 17% (up from 5.1% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Announcement • Feb 17
MRT Inc., Annual General Meeting, Mar 29, 2022 MRT Inc., Annual General Meeting, Mar 29, 2022. Reported Earnings • Nov 15
Third quarter 2021 earnings released: EPS JP¥89.44 (vs JP¥3.78 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥1.61b (up 154% from 3Q 2020). Net income: JP¥504.0m (up JP¥483.0m from 3Q 2020). Profit margin: 31% (up from 3.3% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improved over the past week After last week's 28% share price gain to JP¥2,392, the stock trades at a trailing P/E ratio of 52x. Average trailing P/E is 16x in the Healthcare industry in Japan. Total returns to shareholders of 34% over the past three years. Valuation Update With 7 Day Price Move • Aug 20
Investor sentiment improved over the past week After last week's 16% share price gain to JP¥1,860, the stock trades at a trailing P/E ratio of 40.3x. Average trailing P/E is 16x in the Healthcare industry in Japan. Total loss to shareholders of 7.0% over the past three years. Reported Earnings • Apr 06
Full year 2020 earnings released: EPS JP¥23.59 (vs JP¥4.43 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: JP¥2.56b (up 3.4% from FY 2019). Net income: JP¥131.0m (up 424% from FY 2019). Profit margin: 5.1% (up from 1.0% in FY 2019). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Feb 19
Investor sentiment deteriorated over the past week After last week's 15% share price decline to JP¥1,300, the stock is trading at a trailing P/E ratio of 55.1x, down from the previous P/E ratio of 64.9x. This compares to an average P/E of 20x in the Healthcare industry in Japan. Total return to shareholders over the past three years is a loss of 27%. Is New 90 Day High Low • Feb 17
New 90-day low: JP¥1,348 The company is down 7.0% from its price of JP¥1,452 on 19 November 2020. The Japanese market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 14% over the same period. Reported Earnings • Feb 14
Full year 2020 earnings released: EPS JP¥23.59 (vs JP¥4.43 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: JP¥2.56b (up 3.4% from FY 2019). Net income: JP¥131.0m (up 424% from FY 2019). Profit margin: 5.1% (up from 1.0% in FY 2019). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Announcement • Jan 27
MRT Inc. to Report Fiscal Year 2020 Results on Feb 12, 2021 MRT Inc. announced that they will report fiscal year 2020 results on Feb 12, 2021 Announcement • Jul 17
MRT Inc. to Report Q2, 2020 Results on Aug 11, 2020 MRT Inc. announced that they will report Q2, 2020 results on Aug 11, 2020